ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

MPM Capital

Hunt Technology Ventures

Vida Ventures

Colt Ventures

OrbiMed

OUP (Osage University Partners)

Leaps by Bayer

Solasta Ventures

Bioluminescence Ventures

EcoR1 Capital

Pfizer Venture Investments

Sanofi Ventures

Amgen Ventures

Tekla Capital Management

NS Investment

Matrix Capital Management

Cystic Fibrosis Foundation

ReCode Therapeutics

We're thrilled to announce that the first patient has been dosed in our Phase 1 clinical trial of RCT1100, a novel mRNA-based medicine for patients with primary ciliary dyskinesia (PCD) caused by DNAI1 gene mutations.

This marks a significant step in our efforts to bring innovative therapies to PCD patients who currently have no approved treatment options. RCT1100, developed using our proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform, is designed to restore ciliary function by targeting the disease's root cause.

As we advance this trial, we extend our heartfelt thanks to the PCD community for their ongoing support. Stay tuned for more updates on this groundbreaking journey!

Learn more at https://ThinkPCD.com, and read the full press release here:
https://lnkd.in/guA6BSGR

#pcd #geneticmedicines #patientsfirst #PCDfoundation

As we welcome the New Year, all of us at ReCode Therapeutics are filled with excitement and optimism. 2024 marks not just a change in the calendar but a renewed opportunity for discovery and innovation in our quest to transform the lives of those living with genetic diseases.

We send our well wishes for a year filled with health, happiness, and achievement. To a joyous and prosperous New Year!

As the holiday season unfolds, ReCode Therapeutics extends our warmest wishes to our community, partners, and the families we serve. This time of year reminds us of the importance of connection and compassion.

May this season bring joy, peace, and rejuvenation to you and your loved ones. 

Happy Holidays to all!

#HappyHolidays #TeamReCode

Join the ReCode Therapeutics team, where your passions and drive find a welcoming home. Here, our mantra is clear: "Patients first, always." 

But we're about more than just our platforms. At ReCode, we cultivate an environment where imagination flourishes, passions are fueled, and every voice is heard and valued. Our dedication to diversity and inclusivity has proudly earned us Best Place to Work recognition by the San Francisco Business Times and Silicon Valley Business Journal.

Whether you're a seasoned scientist or a nascent graduate, we have an array of opportunities across various disciplines.

ReCode Your Future:
https://recodetx.com/careers/

#CareerOpportunities #BPTW #PatientFirst

ReCode Therapeutics is a private company founded in 2015 in the USA. The company develops precision genetic medicines using a proprietary delivery platform for the treatment of various genetic diseases, including cystic fibrosis and primary ciliary dyskinesia. ReCode Therapeutics is a multi-platform company developing non-viral nanoparticles for the delivery of diverse RNA- and protein-based therapeutics to targeted tissues and first-in-class tRNA NanoCorrectors for the correction of nonsense mutations causing cystic fibrosis and other diseases.

COM:RECODETX

ReCode Therapeutics

Filings Not Available